テクノロジーは臨床試験における多様性と公平性をどのように推進するのか：IDC Perspective

包括的な臨床開発は、世界中に広がる根深い格差に対処するために不可欠です。臨床試験における包括性と公平性を推進するためには、真の意味での深いコミットメントが必要になります。

当レポートでは、臨床試験における多様性と公平性の推進に関連する既存の状況と重要な課題について、詳細な見解を提供しています。

エグゼクティブスナップショット

概況

• 現在のシナリオ
• 課題はどこにあるのか？
• 臨床試験のD&Iに影響を与える規制の進化
  • オンコロジー研究の承認決定に多様性を統合
• 臨床試験の多様性を高めるために製薬会社が活用する戦略
• D&Iソリューションを提供する主要企業
• 成功の尺度の特定

テクノロジーバイヤーへのアドバイス

参考資料

• 関連調査
• 要約

This IDC Perspective reviews the existing landscape and critical challenges associated with driving diversity and equity in clinical trials. It reviews strategies that pharma is using to address these challenges and scans the evolving technology landscape that is playing a critical role in driving change. It also examines regulatory policies and guidances, identifies the key measures of success, and provides guidance on implementing a diversity strategy."Inclusive clinical development is a must to address the deep-rooted disparities that prevail across the globe. There is no silver bullet to address this issue. It requires a focused, sustained, and collaborative effort; it requires sensitivity and empathy to be woven into technology and strategy; and it calls for a genuine deep-seated commitment toward driving inclusiveness and equity in clinical trials," says Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology at IDC Health Insights.

Executive Snapshot

Situation Overview

• The Current Scenario
• Where Do the Challenges Lie?
• Evolving Regulations That Are Impacting D&I in Clinical Trials
  • Integrating Diversity into Approval Decisions for Oncology Studies
• Strategies Leveraged by Pharma to Increase Diversity in Clinical Trials
• Key Players Providing D&I Solutions
• Identifying Measures of Success

Advice for the Technology Buyer

Learn More

• Related Research
• Synopsis